2-Deoxy-D-glucose prevents and nicotinamide potentiates 3,4-methylenedioxymethamphetamine-induced serotonin neurotoxicity

Journal of Neurochemistry

Volumn 75, Issue 3, 2000, Pages 982-990

  Hervías, Isabel ^a   Lasheras, Berta ^a   Aguirre, Norberto ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

'Ecstacy'; 2 Deoxy D glucose; 3,4 Mehtylenedioxymethamphetamine; 5 Hydroxytryptamine; ATP; Neurotoxicity; Nicotinamide

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DEOXYGLUCOSE; NICOTINAMIDE; SEROTONIN;

ARTICLE; BODY TEMPERATURE; BRAIN REGION; CHEMICAL BINDING; CONTROLLED STUDY; ENERGY METABOLISM; GLUCOSE METABOLISM; HYPOTHERMIA; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ADENOSINE TRIPHOSPHATE; ANIMALS; BODY TEMPERATURE; BRAIN; CARRIER PROTEINS; CORPUS STRIATUM; DOPAMINE; DRUG SYNERGISM; FRONTAL LOBE; HIPPOCAMPUS; HOMOVANILLIC ACID; HYDROXYINDOLEACETIC ACID; HYPOTHERMIA; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE TISSUE PROTEINS; NEUROTOXINS; NIACINAMIDE; ORGAN SPECIFICITY; PAROXETINE; RATS; RATS, WISTAR; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 0033845013     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2000.0750982.x     Document Type: Article

References (58)

1. The role of dopaminergic systems in the perinatal sensitivity to 3,4-methylenedioxymethamphetamine-induced neurotoxicity in rats
2. α-Lipoic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity
3. Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: Possible role in methylenedioxyamphetamine-mediated neurotoxicity
4. 3H]paroxetine-labelled serotonin uptake sites
5. 10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate
6. Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (±)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response
7. Role of metabolic inhibition in methamphetamine and MDMA toxicity: Evidence for decreased mitochondrial function following administration
8. CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxymethamphetamine (MDMA)
9. Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): Evidence from using CuZn-superoxide dismutase transgenic mice
10. Effects of 2-deoxy-D-glucose on methamphetamine-induced dopamine and serotonin neurotoxicity
11. Rapid ATP loss caused by methamphetamine in the mouse striatum: Relationship between energy impairment and dopaminergic neurotoxicity
12. Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion
13. Fenfluramine and norfenfluramine levels in brain microdialysate, brain tissue and plasma of rats administered doses of d-fenfluramine known to deplete 5-hydroxytryptamine levels in brain
14. The spin trap reagent α-phenyl-N-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones
15. The hyperthermic and neurotoxic effects of 'ecstasy' (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metaboliser phenotype
16. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine
17. Role of hyperthermia in the protective action of clomethiazole against MDMA ('ecstasy')-induced neurodegeneration, comparison with the novel NDMA channel blocker ARR15896AR
18. Studies on the neuroprotective effect of pentobarbitone on MDMA-induced neurodegeneration
19. Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration
20. Energy thresholds in brain mitochondria
21. Long-term alteration in the central monoaminergic system of the rat by 2,4,5-trihydroxyamphetamine, 2,4,5-trihydroxymethamphetamine and 3,4-dihydroxymethamphetamine on central tryptophan hydroxylase activity
22. Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX
23. Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin
24. MDMA increases the extracellular concentration of 2,3-dihydroxybenzoic acid in the striatum; evidence for increased hydroxyl radical formation
25. Altered serotonin innervation patterns in the forebrain of monkeys with (±)3,4-methylenedioxymethamphetamine seven years previously: Factors influencing abnormal recovery
26. Metabolism of methylenedioxymethamphetamine: Formation of dihydroxymethamphetamine and quinone identified as its glutathione adduct
27. The temperature dependence of the components of the hepatic microsomal mixed-function oxidases
28. Nicotinamide attenuates methamphetamine-induced striatal dopamine depletion in rats
29. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its congeners
30. Drug metabolism in hypothermia. II. C14 atropine uptake, metabolism and excretion by isolated perfused rat liver
31. Parenteral application of NADH in Parkinson's disease: Clinical improvement partially due to stimulation of endogenous levodopa biosynthesis
32. Ion trap mass spectrometric evidence for the metabolism of 3,4-(methylenedioxy)methamphetamine to the potent neurotoxins 2,4,5-trihydroxymethamphetamine and 2,4,5-trihydroxyamphetamine
33. Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes
34. Excitatory amino acids as the final common pathway for neurologic disorders
35. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat
36. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat
37. 3H]paroxetine binding in rat brain
38. Positron emission tomographic evidence of toxic effect of MDMA ('ecstasy') on brain serotonin neurons in human beings
39. 2,5-bis-(Glutathion-Syl)-α-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations
40. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: Immunocytochemical evidence for neurotoxicity
41. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy')
42. Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA)
43. Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset
44. Activation of glycogen phosphorylase by serotonin and 3,4-methylenedioxymethamphetamine in astroglial-rich primary cultures: Involvement of the 5-HT(2A) receptor
45. 2 receptors
46. Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin
47. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits
48. An integrated hypothesis for the axonal loss induced by 3,4-methylenedioxymethamphetamine
49. Effects of antisense oligonucleotide alteration of MAO-B gene expression on MDMA-induced serotonergic neurotoxicity
50. Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum
51. Is NADH effective in the treatment of Parkinson's disease?
52. Nitric oxide and the neurotoxic effects of methamphetamine and 3,4-methylenedioxymethamphetamine
53. The demethylenation of methylenedioxymethamphetamine ('ecstasy') by debrisoquine hydroxylase (CYP 2D6)
54. NADH stimulates endogenous dopamine biosynthesis by enhancing the recycling of tetrahydrobiopterin in rat phaeochromocytoma cells
55. Effects of methylenedioxymethamphetamine on local cerebral glucose utilization in the rat
56. Effects of salicylate on 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity in rats
57. N-tert-Butyl-alpha-phenylnitrone protects against 3,4-methylenedioxymethamphetamine-induced depletion of serotonin in rats
58. Effects of antihistamines on 3,4-methylenedioxymethamphetamine-induced depletion of serotonin in rats